Gastroesophageal Reflux Disease (GERD) Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | Daewoong Pharma, Takeda, Cinclus Pharma, Renexxion, Addpharma, Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno.N Corporation

DelveInsight's "Gastroesophageal Reflux Disease (GERD) Market Insights, Epidemiology, and Market Forecast 2032" report provides comprehensive insights into the disease landscape, encompassing historical and forecasted epidemiological data, along with an analysis of the Gastroesophageal Reflux Disease market. The report offers valuable information regarding market size, share, emerging trends, and growth prospects across the seven major markets (7MM), including the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Additionally, the report delves into emerging therapies for Gastroesophageal Reflux Disease, providing insights into current treatment methodologies, individual therapy market shares, and a comprehensive evaluation of the market size, spanning from 2019 to 2032. It assesses the existing treatment practices and algorithms for Gastroesophageal Reflux Disease, investigates the key factors influencing market growth, identifies barriers, and highlights unmet medical needs. This comprehensive analysis aims to pinpoint opportunities and gauge the market's inherent potential to address the critical aspects of Gastroesophageal Reflux Disease management.

Learn How the Gastroesophageal Reflux Disease Market is Evolving with the Ongoing Developments @ Gastroesophageal Reflux Disease Market Outlook 

Gastroesophageal Reflux Disease (GERD): An Overview

Gastroesophageal reflux disease (GERD) is a digestive disorder that occurs when acidic stomach juices, or food and fluids back up from the stomach into the esophagus. GERD is the regular, persistent, and long-term occurrence of GER. GERD is caused by multiple different mechanisms that can be intrinsic, structural, or both, leading to the disruption of the esophagogastric junction barrier resulting in exposure of the esophagus to acidic gastric contents.

The pathophysiology of GERD is multifactorial and is best explained by various mechanisms involved, including the influence of the tone of the lower esophageal sphincter, the presence of a hiatal hernia, esophageal mucosal defense against the refluxate and esophageal motility. The typical clinical presentation of GERD is heartburn and regurgitation. However, GERD can also present with various other symptoms that include dysphagia, odynophagia, belching, epigastric pain, and nausea.

The diagnosis of GERD is imprecise as there is no gold standard test available. The diagnosis of GERD is made solely based on presenting symptoms or in combination with other factors such as responsiveness to antisecretory therapy, esophagogastroduodenoscopy, and ambulatory reflux monitoring.

GERD treatment aims to cut down on the amount of reflux or lessen damage to the lining of the esophagus from refluxed materials. Some medications to treat GERD include:- Antacids, H2 Blockers, Proton pump inhibitors (PPIs), Prokinetics. Diet and lifestyle changes are also recommended to help manage GERD.

Gastroesophageal Reflux Disease Market Key Facts

• As per Marco G Patti (2020), 25%-40% of Americans experience symptomatic GERD at some point and about 7%-10% of Americans experience symptoms of GERD on a daily basis. Many individuals control their symptoms with over-the-counter (OTC) medications and without consulting a medical professional, the actual number of individuals with GERD is probably higher.
• As per the article by Peter W. Dettmar et al. (2014), the prevalence of GERD at 10–20% in Europe and the US, but less than 5% in Asia. An estimated 60–70 million Americans are affected by gastrointestinal diseases annually. It is also estimated that 40% of the US population experiences GERD symptoms, with 10–20% of people being affected on a weekly basis.

Get Exclusive Data and Key Insights Shaping the Market Dynamics @ Gastroesophageal Reflux Disease Market Trends

Gastroesophageal Reflux Disease Therapeutics Analysis

The management of GERD can be divided into five stages. Stages I to IV consist of medical management, and stage V entails surgical intervention. The ultimate goal of treatment is to minimize exposure of the esophagus to refluxate, thereby alleviating symptoms, healing the esophagus, preventing complications, and maintaining remission. The treatment for GERD is mainly as follows: (i) lifestyle changes; (ii) medication including PPIs, H2 receptor antagonists, reflux-reducing agents, and adjunct medication; (iii) invasive management including anti-reflux surgery (ARS), bariatric surgery, magnetic sphincter augmentation, and endoscopic therapy.

Most patients with GERD achieve adequate symptom control and esophageal healing through a combination of lifestyle modifications and drug therapy and therefore do not require surgical intervention. Antireflux surgery may be required in patients who continue to have severe symptoms, erosive esophagitis, or disease complications despite adequate pharmacologic therapy.

To improve the treatment scenario, Several major pharma and biotech companies are developing therapies for Gastroesophageal Reflux Disease. Currently, Onconic Therapeutics is leading the therapeutics market with its Gastroesophageal Reflux Disease drug candidates in the most advanced stage of clinical development.

Gastroesophageal Reflux Disease Therapeutic Advancements and Emerging Treatments

• Gastroesophageal Reflux Disease Clinical Trial Progression and Key Companies: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including Daewoong Pharmaceutical, Takeda, Cinclus Pharma, Jeil Pharmaceutical, Renexxion, Addpharma, Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno.N Corporation, among others, are actively engaged in developing novel drugs for potential market entry.
• Gastroesophageal Reflux Disease Emerging and Marketed Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Gastroesophageal Reflux Disease. Some of the emerging therapies in the pipeline include Vonoprazan (Phathom Pharmaceuticals), X842 (Sinorda Biomedicine), BLI5100 (Sebela Pharmaceuticals), Linaprazan glurate (Cinclus Pharma), Naronapride (Renexxion Ireland), Fexuprazan (Daewoong Pharmaceutical), and others.

Recent Developments in the Gastroesophageal Reflux Disease Market

• On Nov. 01, 2023, Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced that the U.S. Food and Drug Administration (FDA) has approved VOQUEZNA® (vonoprazan) tablets 10 mg and 20 mg, a novel potassium-competitive acid blocker (PCAB), as a new treatment for adults for the healing of all grades of Erosive Esophagitis, also known as Erosive GERD (gastroesophageal reflux disease), maintenance of healing of all grades of Erosive GERD, and relief of heartburn associated with Erosive GERD. 
• In May 2023, Phathom Pharmaceuticals announced that it had resubmitted its New Drug Application for vonoprazan for the treatment of Erosive GERD also referred to as erosive esophagitis to the FDA.

Discover Significant Progress and Start Making Informed Decisions @ Clinical, Commercial, and Regulatory Activities in the Gastroesophageal Reflux Disease Market

Gastroesophageal Reflux Disease Market Growth Factors and Associated Trends

The Gastroesophageal Reflux Disease (GERD) market in the seven major markets experiences a multifaceted landscape influenced by several growth factors, drivers, and barriers. One of the primary growth factors is the increasing prevalence of GERD, driven by lifestyle changes, dietary habits, obesity rates, and a rise in the aging population. The demand for effective treatment options and the development of novel therapies have propelled market growth significantly. Additionally, technological advancements and the introduction of minimally invasive procedures, such as laparoscopic anti-reflux surgeries, have enhanced patient outcomes and contributed to market expansion. 

However, several barriers and challenges persist. Regulatory hurdles for novel therapies, stringent approval processes, and the high cost of treatment options pose significant barriers to market growth. Moreover, limited awareness among patients about available treatments, coupled with concerns regarding the long-term use of medications, adds complexity to market expansion efforts. The competitive landscape, marked by patent expirations and generic erosion, also impacts market growth by intensifying pricing pressures. 

Nonetheless, collaborations between pharmaceutical companies and research institutions, coupled with ongoing clinical trials for innovative therapies, signify potential breakthroughs in addressing these barriers, offering prospects for sustainable growth in the GERD market across these major regions.

Gastroesophageal Reflux Disease Market

The report's market outlook section offers a comprehensive understanding of the historical, present, and projected market size. It scrutinizes the influence of existing and upcoming pipeline therapies for Gastroesophageal Reflux Disease. Moreover, it conducts a thorough evaluation of the factors driving and hindering the Gastroesophageal Reflux Disease market, highlighting unmet needs and emerging technologies poised to shape the market's dynamics in the foreseeable future.

The report meticulously outlines the market trends concerning each marketed Gastroesophageal Reflux Disease drug and mid to late-stage pipeline therapies. This evaluation gauges their impact by considering various aspects such as the annual cost of therapy, Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competitive landscape among therapies, brand value, and their collective influence on the market dynamics.

Discover the Anticipated Evolution and Growth of the Market @ Gastroesophageal Reflux Disease Therapeutics Market Forecast

Gastroesophageal Reflux Disease Epidemiology Assessment 

The epidemiology section offers valuable insights into the historical, present, and anticipated trends in Gastroesophageal Reflux Disease epidemiology across the seven major countries (7MM) from 2019 to 2032. This section aims to identify the factors contributing to current and projected Gastroesophageal Reflux Disease epidemiological patterns by examining diverse studies and research findings. Additionally, it furnishes a comprehensive analysis of diagnosed and prevalent patient populations, and future projections, and incorporates perspectives from key opinion leaders to enrich the understanding of this disease landscape.

The Report Covers the Gastroesophageal Reflux Disease Epidemiology, Segmented as -

• Prevalent Cases of Gastroesophageal reflux disease in the 7MM [2019–2032]
• Diagnosed Cases of Gastroesophageal reflux disease in the 7MM [2019–2032]
• Treatable Cases of Gastroesophageal reflux disease in the 7MM [2019–2032]
• Age-specific Prevalent Cases of Gastroesophageal reflux disease in the 7MM [2019–2032]
• Phenotype-specific Prevalent Cases of Gastroesophageal reflux disease in the 7MM [2019–2032]

Gastroesophageal Reflux Disease Drugs Uptake and Pipeline Development Activities

The drug uptake section concentrates on evaluating the adoption rate of newly launched or upcoming potential drugs within the Gastroesophageal Reflux Disease market during the study period. This analysis encompasses the assessment of drug uptake in the Gastroesophageal Reflux Disease market, patient adoption across different therapies, and the sales performance of each drug. Furthermore, the therapeutics assessment section facilitates a comprehensive comprehension of market dynamics by examining drug sales trends, identifying drugs with the highest adoption rates, and elucidating the reasons contributing to the widespread use of specific medications. Additionally, it conducts comparative analyses among Gastroesophageal Reflux Disease drugs, considering their sales performance and respective market shares.

The report encompasses comprehensive coverage of ongoing Gastroesophageal Reflux Disease pipeline development initiatives. It furnishes valuable insights into diverse therapeutic candidates at various developmental stages, elucidating the significant companies actively engaged in creating targeted treatments for Gastroesophageal Reflux Disease. Moreover, it conducts an in-depth analysis of recent advancements, including collaborations, acquisitions, mergers, licensing details, and patent information, providing a holistic view of emerging therapies within the field.

Reports Key Features and Analysis

• Study Period - 2019-32
• Forecast Period - 2023-32
• Geography Coverage - 7MM (United States, EU4 [Germany, Spain, Italy, France], the United Kingdom, and Japan)
• Market Size (by 2032) and Expected CAGR - Download the Sample PDF to Know
• Major Players Shaping the Market Outlook - Daewoong Pharmaceutical, Takeda, Cinclus Pharma, Jeil Pharmaceutical, Renexxion, Addpharma, Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno.N Corporation, among others.
• Emerging and Marketed Therapies Analyzed in the Report - Vonoprazan (Phathom Pharmaceuticals), X842 (Sinorda Biomedicine), BLI5100 (Sebela Pharmaceuticals), Linaprazan glurate (Cinclus Pharma), Naronapride (Renexxion Ireland), Fexuprazan (Daewoong Pharmaceutical), and many more.

For In-depth Insights, Key Report Offerings, and TOC; Access the Sample PDF File @ Gastroesophageal Reflux Disease Therapeutics Market Outlook and Forecast

Related Reports:

• Gastroesophageal Reflux Disease Epidemiology Forecast

Gastroesophageal Reflux Disease Epidemiology Forecast report delivers an in-depth understanding of the Gastroesophageal Reflux Disease, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

• Gastroesophageal Reflux Disease Pipeline Insight

Gastroesophageal Reflux Disease Pipeline Insight report, provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Gastroesophageal Reflux Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

Healthcare Consulting and Market Research Services by DelveInsight

Unlock key insights and innovation in the healthcare industry with our cutting-edge market research services, paving the way for informed decisions and competitive advantage in this rapidly evolving industry @ Medical Device Consulting Services

Dive Into Success Stories in the Healthcare Market

Discover how DelveInsight assisted a Swedish pharmaceutical client in identifying potential licensing partners for their proprietary neonatal mesenchymal stem cells (MSCs). Download the Out Licensing Opportunity Case Study!

About DelveInsight:

DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance.

  Contact Information:

Shruti Thakur (Manager, Marketing and IB)

info@delveinsight.com

www.delveinsight.com

Connect with DelveInsight: LinkedIn | Facebook | Twitter